Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND IBUPROFEN vs SUMATRIPTAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve transmission.
Temporary relief of minor aches and pains,Reduction of fever,Off-label: Management of osteoarthritis pain, headache, dysmenorrhea
Acute treatment of migraine with or without aura,Acute treatment of cluster headache episodes
Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.
Sumatriptan is available as oral tablets (25 mg, 50 mg, 100 mg), subcutaneous injection (6 mg/0.5 m L), and nasal spray (5 mg, 20 mg). For acute migraine: oral: 50-100 mg at onset, may repeat after 2 hours (max 200 mg/day). Subcutaneous: 6 mg at onset, may repeat after 1 hour (max 12 mg/24h). Nasal spray: 20 mg in one nostril at onset, may repeat after 2 hours (max 40 mg/day).
Acetaminophen: 2-3 hours (normal hepatic function). Ibuprofen: 2-4 hours (immediate-release); prolonged in overdose or hepatic impairment.
2.5 hours (range 1–4 h); clinically relevant for redosing interval of ≥2 h.
Acetaminophen is primarily metabolized via glucuronidation and sulfation; a minor pathway via CYP2E1 produces a toxic metabolite, NAPQI. Ibuprofen is metabolized primarily by CYP2C9 and to a lesser extent by CYP2C8.
Primarily via monoamine oxidase A (MAO-A); minor via cytochrome P450 (CYP) enzymes.
Acetaminophen: renal excretion of metabolites (glucuronide 55%, sulfate 30%, cysteine/mercapturate <10%); <5% unchanged. Ibuprofen: renal excretion of metabolites (conjugates) 90%; <10% unchanged; minor biliary/fecal.
60% renal (as indole acetic acid metabolite), 40% fecal; <3% unchanged in urine.
Acetaminophen: 10-25% (albumin). Ibuprofen: >99% (albumin).
14–21%, primarily to albumin and alpha-1-acid glycoprotein.
Acetaminophen: 0.9 L/kg; Ibuprofen: 0.15 L/kg (highly protein-bound, low Vd).
2.0–3.3 L/kg; indicates extensive tissue distribution.
Acetaminophen: 75-85% oral. Ibuprofen: 80-100% oral.
Oral: 15% (due to first-pass metabolism); subcutaneous: 97%; intranasal: 17% (with variability).
GFR 30-59: Caution, use lowest effective dose; GFR <30: Contraindicated due to ibuprofen component.
No specific dose adjustment is recommended for renal impairment. However, sumatriptan and its metabolites are excreted renally, and caution is advised in severe renal impairment (Cr Cl <15 m L/min). No specific GFR-based guidelines are established.
Child-Pugh A: No adjustment; Child-Pugh B: Caution, reduce acetaminophen dose; Child-Pugh C: Contraindicated.
Contraindicated in severe hepatic impairment (Child-Pugh C). For mild to moderate hepatic impairment (Child-Pugh A or B): oral maximum dose is 50 mg; nasal spray: 5 mg single dose; subcutaneous: no specific adjustment, but caution advised due to reduced clearance.
Weight-based: 10-15 mg/kg acetaminophen + 5-10 mg/kg ibuprofen per dose, every 6-8 hours, max 4 doses/day.
Not approved for pediatric use <18 years. However, off-label: adolescent (12-17 years): oral 25-100 mg at onset, may repeat after 2 hours (max 200 mg/day). Subcutaneous: 3-6 mg at onset (based on weight, e.g., 0.06 mg/kg). Nasal spray: 5-20 mg at onset.
Use lowest effective dose; monitor renal function due to ibuprofen; avoid durations >10 days.
Limited data in elderly. Start with the lowest effective dose (e.g., oral 25 mg, subcutaneous 3 mg, nasal spray 5 mg). Caution due to potential for cardiovascular risk, hypertension, and reduced hepatic/renal function. Avoid in patients with uncontrolled hypertension or ischemic heart disease.
Acetaminophen may cause severe liver injury, including acute liver failure, at doses exceeding 4,000 mg/day. Ibuprofen: NSAIDs increase risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use and in patients with cardiovascular risk factors. NSAIDs also increase risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of stomach or intestines.
Not recommended for use in patients with risk factors for coronary artery disease (e.g., hypertension, diabetes, smoking) unless a cardiovascular evaluation confirms absence of coronary artery disease.
Acetaminophen: Hepatotoxicity risk with excessive doses, use with caution in hepatic impairment, avoid with alcohol use >3 drinks/day. Ibuprofen: Cardiovascular risk, gastrointestinal bleeding, renal toxicity, hypertension, fluid retention, avoid late pregnancy.
Risk of myocardial ischemia, infarction, and Prinzmetal's angina,Life-threatening serotonin syndrome with concomitant serotonergic drugs,Elevations in blood pressure,Increased risk of cerebrovascular events,Overuse headache with frequent use
Acetaminophen: Severe hepatic impairment, allergy to acetaminophen. Ibuprofen: Hypersensitivity to ibuprofen or other NSAIDs, history of asthma/urticaria after NSAIDs, perioperative pain in CABG surgery, severe heart failure, active GI bleeding, late pregnancy.
Ischemic heart disease,History of myocardial infarction,Uncontrolled hypertension,Hemiplegic or basilar migraine,Concomitant use of MAO-A inhibitors or within 2 weeks of discontinuation,Severe hepatic impairment,Hypersensitivity to sumatriptan
Avoid alcohol; take with food or milk to minimize GI irritation. No specific food restrictions.
No significant food interactions. Avoid alcohol during migraine attacks as it can worsen headaches. May be taken with or without food.
First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibuprofen is relatively safe but may cause oligohydramnios. Third trimester: Acetaminophen is safe; ibuprofen is contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
FDA Pregnancy Category C. In first trimester, no increased risk of major congenital malformations from available data; however, animal studies show embryo lethality and increased malformations at high doses. Second and third trimester risks include potential for uterine hypertonus and fetal hypoxia during maternal use for migraine attacks; avoid during third trimester due to risk of premature uterine contractions.
Acetaminophen: low levels in breast milk, M/P ratio ~0.9; considered compatible with breastfeeding. Ibuprofen: minimal excretion, M/P ratio ~0.01; considered compatible. Combination: low risk with recommended doses.
Sumatriptan is excreted into human breast milk with a relative infant dose of 3.5% of maternal weight-adjusted dose (M/P ratio approximately 0.6-4.3). Clinical studies show no adverse effects in breastfed infants; however, wait at least 12 hours after injection or 24 hours after oral dose to breastfeed to minimize exposure.
No standard adjustment for acetaminophen; ibuprofen dosing unchanged in pregnancy but avoid in third trimester; consider increased clearance of acetaminophen in pregnancy but no dose adjustment recommended.
No specific dose adjustments required for pregnancy based on pharmacokinetic changes; however, lower starting doses may be considered due to increased sensitivity to vascular effects. Avoid use in preeclampsia or uncontrolled hypertension.
Combination product for acute pain; fixed-dose may exceed recommended daily acetaminophen limit if other acetaminophen-containing products are used. Onset of ibuprofen is 30-60 min, acetaminophen 15-30 min; duration 4-6 hours. Caution in renal impairment (ibuprofen) and hepatic impairment (acetaminophen). Avoid in third trimester of pregnancy.
Sumatriptan is a 5-HT1B/1D receptor agonist used for acute migraine. It is available in oral, nasal, subcutaneous, and rectal formulations. Onset of action is fastest with subcutaneous injection (10-15 minutes). Avoid use within 24 hours of other triptans or ergot alkaloids. Contraindicated in patients with ischemic heart disease, cerebrovascular disease, uncontrolled hypertension, or hemiplegic/basilar migraine. Monitor for serotonin syndrome when combined with SSRIs/SNRIs.
Do not exceed 10 tablets (500 mg acetaminophen/200 mg ibuprofen) per day.,Do not take with other products containing acetaminophen or NSAIDs.,Take with food or milk to reduce stomach upset.,Avoid alcohol while taking this medication.,Seek medical help if pain persists >10 days or fever >3 days.,Store at room temperature, away from moisture.
Take sumatriptan at the first sign of migraine headache for best results.,Do not exceed the recommended dose: maximum 100 mg orally or 20 mg intranasally per single dose, with a maximum of 200 mg daily for oral formulations.,Seek emergency medical attention if you experience chest pain, shortness of breath, irregular heartbeat, or signs of stroke.,Avoid driving or operating machinery until you know how sumatriptan affects you, as it may cause dizziness or drowsiness.,Inform your doctor if you have heart disease, high blood pressure, or are pregnant or breastfeeding.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
"Concurrent use of sumatriptan, a serotonin 5-HT1B/1D receptor agonist, and rasagiline, a selective monoamine oxidase B (MAO-B) inhibitor, can lead to serotonin syndrome due to excessive serotonergic activity in the central nervous system. Rasagiline inhibits the metabolism of serotonin, while sumatriptan indirectly increases serotonin release; their combination may result in life-threatening neuromuscular excitation, autonomic instability, and altered mental status. Symptoms may include hyperthermia, rigidity, myoclonus, and rapid fluctuations in vital signs, requiring immediate medical intervention."
"Sumatriptan, a 5-HT1B/1D receptor agonist used for migraine, and sulpiride, a dopamine D2 receptor antagonist with atypical antipsychotic properties, may exhibit additive or synergistic effects on the central nervous system. This combination can potentially increase the risk of serotonin syndrome (due to sumatriptan's serotonergic activity) and may also lead to enhanced extrapyramidal symptoms or neuroleptic malignant syndrome via combined dopaminergic antagonism. Clinical outcomes may include hyperthermia, rigidity, altered mental status, and autonomic instability."
"The combination of sumatriptan (a 5-HT1B/1D receptor agonist) and paroxetine (a selective serotonin reuptake inhibitor) increases the risk of serotonin syndrome, a potentially life-threatening condition characterized by neuromuscular excitation, autonomic instability, and altered mental status. This interaction is due to additive serotonergic effects, as both drugs enhance serotonin activity in the central nervous system. Clinical outcomes range from mild symptoms (tremor, hyperreflexia, diaphoresis) to severe manifestations (hyperthermia, rigidity, seizures) and require immediate medical attention."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND IBUPROFEN vs SUMATRIPTAN, answered by our medical review team.
ACETAMINOPHEN AND IBUPROFEN is a NSAID that works by Acetaminophen is a centrally acting analgesic and antipyretic whose exact mechanism is not fully understood, but is thought to involve inhibition of cyclooxygenase (COX) in the brain and modulation of cannabinoid receptors. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that non-selectively inhibits COX-1 and COX-2, reducing prostaglandin synthesis.. SUMATRIPTAN is a 5-HT1 Agonist that works by Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND IBUPROFEN and SUMATRIPTAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND IBUPROFEN is: Oral: Acetaminophen 325 mg and ibuprofen 200 mg, 1-2 tablets every 6 hours as needed, not exceeding 6 tablets/24 hours.. The standard adult dose of SUMATRIPTAN is: Sumatriptan is available as oral tablets (25 mg, 50 mg, 100 mg), subcutaneous injection (6 mg/0.5 m L), and nasal spray (5 mg, 20 mg). For acute migraine: oral: 50-100 mg at onset, may repeat after 2 hours (max 200 mg/day). Subcutaneous: 6 mg at onset, may repeat after 1 hour (max 12 mg/24h). Nasal spray: 20 mg in one nostril at onset, may repeat after 2 hours (max 40 mg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN AND IBUPROFEN and SUMATRIPTAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND IBUPROFEN is classified as Category D/X. First trimester: Acetaminophen is considered low risk; ibuprofen is associated with increased risk of miscarriage and cardiac defects. Second trimester: Acetaminophen is safe; ibup. SUMATRIPTAN is classified as Category D/X. FDA Pregnancy Category C. In first trimester, no increased risk of major congenital malformations from available data; however, animal studies show embryo lethality and increased m. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.